CAS:129938-20-1
MF:C21H24ClNO
It belonging to the class of SSRIs, was the first drug originally approved for the on-demand treatment of men with PE by seven European countries in 2008.
Premature ejaculation (PE) is the most common male sexual dysfunction. It is a short-acting SSRI. It is differentiated from the existing SSRI treatments for PE by the fact that it can be administered on an as-needed basis.
- Description
- Additional information
Description
CAS 129938-20-1 Product Information
| Product Name: | CAS 129938-20-1 |
| Synonyms: | N-Dimethyl-3-naphthalen-1-yloxy-1-phenyl-propan-1-amine hydrochloride;S-(+)-N,N-dimethyl-a-[2-(naphthalenyloxy)ethyl] benzenemethanamine hydrochloride, LY-210448 hydrochloride;(1s)-n,n-dimethyl-3-naphthalen-1-yloxy-1-phenyl-propan-1-amine hydrochloride;Rimonabant 75000;(aS)-N,N-Dimethyl-a-[2-(1-naphthalenyloxy)ethyl]benzenemethanamine;LY-21044;((S)-(+)-N,N-Dimethyl-1-phenyl-3-(1-naphthalenyloxy)propanamine hydrochloride) |
| CAS NO: | 129938-20-1 |
| Molecular Weight: | 341.874 |
| Molecular Formula: | C21H24ClNO |
| Boiling Point: | 454.4ºC at 760 mmHg |
| Melting point: | 175-179ºC |
| Appearance: | White power |
| Applications: | It is a short-acting novel selective serotonin reuptake inhibitor marketed for the treatment of premature ejaculation in men. |
| Storage: | room temp |
CAS 129938-20-1 uses/what is CAS 129938-20-1 used for
It is used to treat premature ejaculation in adult men aged 18-64years. It works by increasing the serotonin level in the nervous system; this increases the time it takes to ejaculate and could improve control over ejaculation.
CAS 129938-20-1 side effects
- Dizziness.
- Nervousness and confusion.
- Excessive sweating.
- Headache.
- Diarrhoea.
- Decreased libido.
- Blurred vision.
- Ringing or buzzing in the ears.
CAS 129938-20-1 Synthesis
It can be synthesized in four chemical steps starting from R-1phenyl- 1,3-propanediol via selective tosylation of the primary hydroxy group with p-toluenesulfonyl chloride, triethylamine and 4-(dimethylamino) pyridine (DMAP), and subsequent condensation with 1naphthol by means of sodium- or lithium hydroxide to yield R-3-(1naphthyloxy)- 1-phenylpropanol as the key intermediate. Conversion of the alcohol group to the corresponding mesylate with methanesulfonyl chloride, triethylamine, and DMAP, followed by treatment with dimethylamine affords it, which is then acidified to its hydrochloride salt.
Additional information
| Color | White |
|---|---|
| Form | Powder |
Reviews
There are no reviews yet.